PARK2 adenovirus

The PARK2 gene, also known as Parkin RBR E3 ubiquitin-protein ligase, is a key gene located on chromosome 6 (6q26) that encodes the Parkin protein. This protein plays a key role in the ubiquitin-proteasome system, crucial for the degradation of damaged or misfolded proteins, thereby maintaining cellular homeostasis. PARK2 gene mutations are strongly associated with autosomal recessive juvenile Parkinson''s disease (AR-JP), an early-onset form of Parkinson''s disease (PD). Parkin, as an E3 ubiquitin ligase, marks specific proteins for proteasomal degradation and is involved in mitochondrial quality control, mitophagy, and oxidative stress responses. Loss of Parkin function leads to the accumulation of toxic protein aggregates and mitochondrial dysfunction, contributing to neurodegeneration. PARK2 has become a key target for gene therapy research, particularly in Parkinson''s disease and other neurodegenerative disorders.

The PARK2 adenovirus is a recombinant adenoviral vector designed to deliver the human PARK2 gene to target cells or tissues for research or therapeutic purposes. Adenoviruses are widely used in gene therapy due to their high transduction efficiency, ability to infect both dividing and non-dividing cells, and relatively large genetic material loading capacity. The PARK2 adenovirus is designed to overexpress the Parkin protein, enabling researchers to study its functional mechanisms in cellular and animal models of Parkinson''s disease. Furthermore, this viral vector has the potential for gene therapy applications aimed at restoring Parkin function in patients with PARK2 mutations. This adenovirus system ensures stable and transient gene expression, making it suitable for experimental studies investigating neuroprotection, mitophagy enhancement, and protein degradation pathways.